Actively Recruiting
A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2025-04-10
21
Participants Needed
1
Research Sites
782 weeks
Total Duration
On this page
Sponsors
T
Tianjin Medical University Cancer Institute and Hospital
Lead Sponsor
N
Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer
CONDITIONS
Official Title
A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and sign a written informed consent document
- Age between 18 and 70 years, male or female
- Histopathologically confirmed advanced or metastatic pancreatic cancer
- Failed or intolerant to standard treatment for pancreatic cancer
- Positive mesothelin expression
- At least one measurable lesion at baseline according to RECIST version 1.1
- Expected survival time of more than 12 weeks
- ECOG performance status of 0 to 1
- Adequate organ functions
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Actively Recruiting
Research Team
J
Jihui Hao, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here